Loading stock data…
INSM
$103.89+2.59 (+2.56%)
Pre-Market$105.00+1.11 (+1.07%)· Last close May 11
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insmed Incorporated in the Healthcare sector is trading at $103.89. The stock is currently 51% below its 52-week high of $212.75, remaining 33.3% below its 200-day moving average. Technical signals show oversold RSI of 22 and bearish MACD signal, explaining why INSM maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 22) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$103.89
Potential Upside
5%
Whystock Fair Value$109.08
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Mean target$204.75+97.1%
Range$140.00 – $243.00
Fundamentals
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial l...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.89B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-139.97%
Volume
Today's trading volume
7.87M
Recent News
Here's What Analysts Are Forecasting For Insmed Incorporated (NASDAQ:INSM) After Its First-Quarter Results
There's been a major selloff in Insmed Incorporated ( NASDAQ:INSM ) shares in the week since it released its quarterly...
Insmed Stock Sell-off is Overdone as Underlying Metrics Appear Positive, RBC Says
Insmed (INSM) stock sell-off post Q1 results is overdone as underlying metrics appear positive and p
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.
US Stock Market Today: S&P 500 Futures Climb As Traders Weigh Jobs And Inflation
The Morning Bull - US Market Morning Update Friday, May, 8 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.4% and Nasdaq-100 futures up roughly 0.6%, as investors focus on a key mix of jobs and inflation signals. The April non-farm payrolls report is expected to show 62,000 new jobs, unemployment at 4.3% and paychecks rising 0.3% month on month, which hints at an economy that is cooling but still holding up. At the same time, global food prices...
Insmed Q1 Earnings Call Highlights
Insmed (NASDAQ:INSM) executives said the company entered 2026 with strong commercial momentum for BRINSUPRI and continued growth for ARIKAYCE, while advancing late-stage development of TPIP across multiple Phase III studies. Management reiterated full-year guidance for both commercial products and s